Go Pro
→ He turned $12,415 into millions. Now he wants to help you. (From Tim Sykes) (Ad)tc pixel Free SMTI Stock Alerts

Sanara MedTech (SMTI) Financials

Sanara MedTech logo
$24.84 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$24.84 0.00 (-0.02%)
As of 07/2/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Sanara MedTech

Annual Income Statements for Sanara MedTech

This table shows Sanara MedTech's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -1.61 -0.68 0.19 -0.73 -2.81 -4.36 -7.92 -7.94 -4.30 -9.66 -38
Consolidated Net Income / (Loss)		 -1.34 -0.42 0.33 -0.60 -2.81 -4.45 -7.99 -8.09 -4.44 -9.91 -38
Net Income / (Loss) Continuing Operations		 -1.34 -0.42 0.33 -0.60 -2.84 -4.45 -7.99 -8.09 -4.44 -1.94 -0.39
Total Pre-Tax Income 		-1.34 -0.42 0.33 -0.60 -2.84 -4.45 -7.99 -14 -4.44 -1.94 -0.39
Total Operating Income		 -0.96 -0.27 0.12 -0.50 -2.74 -5.03 -7.38 -13 -4.22 1.26 7.30
Total Gross Profit		 2.48 4.56 5.50 5.33 11 14 22 39 57 79 96
Total Revenue		 3.37 5.51 6.30 5.84 12 16 24 46 65 87 103
Operating Revenue		 3.37 5.51 6.30 5.84 12 16 24 46 65 87 103
Total Cost of Revenue		 0.89 0.94 0.81 0.51 1.21 1.62 2.31 6.36 7.85 8.14 7.52
Operating Cost of Revenue		 0.89 0.94 0.81 0.51 1.21 1.62 2.31 6.36 7.85 8.14 7.52
Total Operating Expenses		 3.45 4.84 5.38 5.83 13 19 29 52 61 77 88
Selling, General & Admin Expense		 3.38 4.76 5.28 5.74 13 19 28 46 57 72 79
Research & Development Expense		 - - - - - 0.04 0.56 3.37 4.13 2.83 5.07
Depreciation Expense		 0.06 0.06 0.08 0.08 0.12 0.29 0.60 2.37 3.68 2.79 2.66
Other Operating Expenses / (Income)		 0.01 0.01 0.02 0.01 0.11 - - 0.28 -3.45 -0.01 0.00
Impairment Charge		 - - - - - - - - - 0.00 1.84
Total Other Income / (Expense), net		 -0.38 -0.14 0.21 -0.10 -0.10 0.59 -0.62 -1.42 -0.22 -3.20 -7.70
Interest Expense		 0.38 0.17 -0.16 0.09 0.11 -0.57 0.00 0.00 0.48 3.13 6.76
Interest & Investment Income		 0.00 0.00 0.00 -0.02 - 0.00 -0.62 -1.42 0.25 -0.07 -0.95
Other Income / (Expense), net		 -0.00 0.03 0.05 0.01 0.01 0.01 - - - 0.00 0.01
Net Income / (Loss) Discontinued Operations		 - - - - - - - - - -7.97 -37
Net Income / (Loss) Attributable to Noncontrolling Interest		 - - - - - -0.09 -0.07 -0.15 -0.14 -0.25 -0.01
Basic Earnings per Share		 ($0.02) ($0.01) $0.00 $0.00 ($1.32) ($0.76) ($1.08) ($1.00) ($0.52) ($1.14) ($4.36)
Weighted Average Basic Shares Outstanding		 106.70M 108.60M 111.38M 217.16M 2.13M 5.73M 7.34M 7.91M 8.28M 8.48M 8.62M
Diluted Earnings per Share		 ($0.02) ($0.01) $0.00 $0.00 ($1.32) ($0.76) - ($1.00) ($0.52) ($1.14) ($4.36)
Weighted Average Diluted Shares Outstanding		 - 108.60M 208.65M 217.16M 2.13M 5.73M 7.34M 7.91M 8.28M 8.48M 8.62M
Weighted Average Basic & Diluted Shares Outstanding		 - 110.54M 236.64M - 6.02M 5.73M 7.34M 8.38M 8.62M 8.90M 9.17M

Quarterly Income Statements for Sanara MedTech

This table shows Sanara MedTech's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -1.06 -0.24 -1.76 -3.50 -2.86 -1.54 -3.53 -2.01 -30 -1.61 0.46
Consolidated Net Income / (Loss)		 -1.09 -0.26 -1.80 -3.53 -2.88 -1.70 -3.53 -2.02 -30 -1.61 0.46
Net Income / (Loss) Continuing Operations		 -1.09 -0.26 -1.80 -3.53 -0.18 -1.70 -0.62 -2.02 0.83 4.33 0.40
Total Pre-Tax Income 		-1.09 -0.26 -1.80 -3.53 -0.18 -1.70 -0.62 -2.02 0.83 4.33 0.40
Total Operating Income		 -0.91 -0.23 -1.53 -2.88 0.78 -0.37 0.83 -0.03 2.94 6.47 2.65
Total Gross Profit		 14 16 17 18 20 24 22 24 24 26 26
Total Revenue		 16 18 19 20 22 26 23 26 26 28 28
Operating Revenue		 16 18 19 20 22 26 23 26 26 28 28
Total Cost of Revenue		 1.75 1.79 1.89 2.01 1.99 2.25 1.83 1.94 1.87 1.87 1.92
Operating Cost of Revenue		 1.75 1.79 1.89 2.01 1.99 2.25 1.83 1.94 1.87 1.87 1.92
Total Operating Expenses		 15 16 18 21 19 24 21 24 22 19 23
Selling, General & Admin Expense		 14 16 16 19 17 22 19 22 20 16 22
Research & Development Expense		 0.99 0.65 0.95 0.99 0.78 2.41 0.95 1.26 1.03 1.67 0.76
Depreciation Expense		 1.00 1.09 1.11 1.11 0.70 1.61 0.69 1.11 0.61 -0.19 0.59
Total Other Income / (Expense), net		 -0.19 -0.04 -0.27 -0.64 -0.96 -1.33 -1.45 -1.99 -2.11 -2.15 -2.25
Interest Expense		 0.19 0.29 0.27 0.64 0.93 1.29 1.32 1.79 1.82 1.83 1.80
Interest & Investment Income		 0.00 - 0.00 0.00 -0.03 - -0.14 -0.20 -0.29 -0.32 -0.45
Other Income / (Expense), net		 - - 0.00 - 0.00 - 0.01 - 0.00 - 0.00
Net Income / (Loss) Discontinued Operations		 - - - - -2.70 - -2.91 - -31 - 0.06
Net Income / (Loss) Attributable to Noncontrolling Interest		 -0.03 -0.03 -0.03 -0.03 -0.03 -0.16 -0.00 -0.00 -0.00 -0.00 -0.00
Basic Earnings per Share		 ($0.13) ($0.03) ($0.21) ($0.41) ($0.34) ($0.18) ($0.41) ($0.23) ($3.52) ($0.20) $0.05
Weighted Average Basic Shares Outstanding		 8.33M 8.28M 8.42M 8.47M 8.52M 8.48M 8.57M 8.61M 8.65M 8.62M 8.71M
Diluted Earnings per Share		 ($0.13) ($0.03) ($0.21) ($0.41) ($0.34) ($0.18) ($0.41) ($0.23) ($3.40) ($0.32) $0.05
Weighted Average Diluted Shares Outstanding		 8.33M 8.28M 8.42M 8.47M 8.52M 8.48M 8.57M 8.61M 8.94M 8.62M 8.99M
Weighted Average Basic & Diluted Shares Outstanding		 8.54M 8.62M 8.63M 8.75M 8.74M 8.90M 8.89M 8.90M 8.94M 9.17M 9.16M

Annual Cash Flow Statements for Sanara MedTech

This table details how cash moves in and out of Sanara MedTech's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -0.34 0.65 -0.37 0.27 6.44 -6.16 18 -9.69 -3.81 11 0.70
Net Cash From Operating Activities		 -1.20 0.41 -0.14 0.28 -2.17 -4.03 -4.81 -5.55 -3.25 -0.02 6.79
Net Cash From Continuing Operating Activities		 -0.34 1.11 0.84 -1.44 -2.17 -4.03 -4.81 -5.55 -3.25 -0.02 6.79
Net Income / (Loss) Continuing Operations		 -1.34 -0.42 0.33 -0.60 -2.84 -4.45 -7.99 -8.09 -4.44 -9.91 -38
Consolidated Net Income / (Loss)		 -1.34 -0.42 0.33 -0.60 -2.84 -4.45 -7.99 -8.09 -4.44 -9.91 -38
Depreciation Expense		 0.06 0.06 0.08 0.08 0.12 0.29 0.60 2.37 3.68 4.92 3.95
Amortization Expense		 - - - - - - - 0.00 0.01 0.21 0.28
Non-Cash Adjustments To Reconcile Net Income		 0.18 1.16 -0.20 0.09 0.41 2.34 3.76 5.49 0.71 8.22 41
Changes in Operating Assets and Liabilities, net		 -0.10 -0.39 -0.35 0.71 0.14 -2.22 -1.18 -5.33 -3.20 -3.46 -1.15
Net Cash From Investing Activities		 -0.01 -0.00 -0.09 -0.01 -1.20 -2.74 -5.28 -3.51 -10 -6.61 -15
Net Cash From Continuing Investing Activities		 -0.01 -0.00 -0.09 -0.01 -1.20 -2.74 -5.28 -3.51 -10 -6.61 -15
Purchase of Property, Plant & Equipment		 -0.01 -0.00 -0.04 -0.01 -0.18 -0.54 -0.17 -0.15 -0.27 -0.21 -4.63
Acquisitions		 - 0.00 -0.04 0.00 -1.52 -2.20 -5.11 -3.37 -9.94 -5.33 -10
Sale of Property, Plant & Equipment		 - - - - 0.00 - 0.00 0.00 0.00 0.00 0.06
Other Investing Activities, net		 - - - - -0.00 - - - 0.00 -1.08 0.00
Net Cash From Financing Activities		 0.87 0.24 -0.14 0.00 9.80 0.62 28 -0.63 9.64 17 8.89
Net Cash From Continuing Financing Activities		 0.87 0.24 -0.14 0.00 9.80 0.62 28 -0.63 9.64 17 8.89
Repayment of Debt		 -1.17 -0.20 -0.19 0.00 -2.20 0.00 -1.24 -0.41 -0.14 -9.88 -2.20
Issuance of Debt		 1.30 - - - 2.20 0.58 0.80 0.00 9.69 29 12
Issuance of Common Equity		 - - - - 10 0.04 29 0.00 0.91 -0.08 0.00
Other Financing Activities, net		 -0.00 -0.00 -0.00 0.00 - - - 0.00 -0.82 -2.02 -0.94
Cash Interest Paid		 0.09 0.05 0.01 0.00 0.04 0.00 0.00 0.00 0.28 1.58 3.35
Cash Income Taxes Paid		 0.00 0.00 0.00 0.00 0.00 0.00 - - - 0.04 0.05

Quarterly Cash Flow Statements for Sanara MedTech

This table details how cash moves in and out of Sanara MedTech's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 0.18 -1.09 -2.32 3.32 10 -0.40 4.81 -3.73 -2.02 1.64 -2.98
Net Cash From Operating Activities		 1.06 -0.85 -1.59 -1.41 2.05 0.93 -2.00 2.66 2.18 3.95 -2.47
Net Cash From Continuing Operating Activities		 1.06 -0.85 -1.59 -1.41 2.05 0.93 -2.00 2.66 2.18 3.95 -2.47
Net Income / (Loss) Continuing Operations		 -1.09 -0.26 -1.80 -3.53 -2.88 -1.70 -3.53 -2.02 -30 -1.61 0.46
Consolidated Net Income / (Loss)		 -1.09 -0.26 -1.80 -3.53 -2.88 -1.70 -3.53 -2.02 -30 -1.61 0.46
Depreciation Expense		 1.00 1.09 1.11 1.11 1.10 1.61 1.12 1.11 1.04 0.67 0.59
Amortization Expense		 0.00 0.00 0.00 0.10 0.05 0.06 0.06 0.07 0.07 0.07 0.07
Non-Cash Adjustments To Reconcile Net Income		 0.78 0.58 0.27 1.73 3.62 3.15 0.16 4.46 32 4.65 -1.20
Changes in Operating Assets and Liabilities, net		 0.38 -2.26 -1.18 -0.81 0.16 -2.18 0.19 -0.96 -0.54 0.16 -2.38
Net Cash From Investing Activities		 -10 -0.05 -0.07 -0.06 -6.36 -0.13 -5.18 -3.93 -3.42 -2.45 -0.04
Net Cash From Continuing Investing Activities		 -10 -0.05 -0.07 -0.06 -6.36 -0.13 -5.18 -3.93 -3.42 -2.45 -0.04
Purchase of Property, Plant & Equipment		 -0.17 -0.05 -0.07 -0.06 -0.01 -0.07 -1.72 -1.76 -1.06 -0.08 -0.04
Acquisitions		 - - 0.00 - -5.27 -0.06 -3.52 -2.17 -2.36 -2.36 0.00
Sale of Property, Plant & Equipment		 - - 0.00 - - - 0.06 - - - 0.00
Net Cash From Financing Activities		 9.22 -0.19 -0.66 4.79 14 -1.20 12 -2.47 -0.77 0.14 -0.48
Net Cash From Continuing Financing Activities		 9.22 -0.19 -0.66 4.79 14 -1.20 12 -2.47 -0.77 0.14 -0.48
Repayment of Debt		 0.28 0.01 -0.58 -9.24 -0.02 -0.04 0.00 -2.34 -0.07 0.22 -0.40
Issuance of Debt		 9.69 - 0.00 14 15 - 12 -0.04 - - 0.00
Other Financing Activities, net		 -0.74 -0.08 -0.08 -0.08 -0.70 -1.16 -0.08 -0.08 -0.70 -0.08 -0.08
Cash Interest Paid		 0.15 0.14 0.21 0.34 0.40 0.63 0.63 0.89 0.91 0.92 1.52
Cash Income Taxes Paid		 - - - - - - 0.05 - - - 0.00

Annual Balance Sheets for Sanara MedTech

This table presents Sanara MedTech's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 1.39 2.17 2.22 1.71 11 9.83 36 61 74 88 73
Total Current Assets		 1.16 2.00 2.04 1.69 8.86 4.48 25 21 19 33 34
Cash & Equivalents		 0.18 0.83 0.46 0.18 6.61 0.46 19 8.96 5.15 16 17
Accounts Receivable		 0.25 0.74 0.79 1.02 1.29 2.22 2.94 6.90 8.48 14 12
Inventories, net		 0.41 0.35 0.71 0.47 0.75 1.15 2.05 3.55 4.72 2.75 3.95
Prepaid Expenses		 0.11 0.02 0.03 0.03 0.16 0.61 0.92 1.10 0.61 1.02 0.95
Other Current Nonoperating Assets		 - - - - - - - - - 0.10 0.07
Plant, Property, & Equipment, net		 0.04 0.03 0.06 0.02 0.20 0.68 1.63 1.42 1.26 0.43 0.46
Total Noncurrent Assets		 0.19 0.14 0.12 0.00 2.06 4.67 10 39 54 54 39
Long-Term Investments		 - - - - 0.00 1.10 5.02 3.08 3.08 6.21 15
Goodwill		 - - - - - - 0.00 3.60 3.60 3.60 3.60
Intangible Assets		 0.19 0.14 0.12 0.00 1.47 3.10 4.73 32 45 23 19
Other Noncurrent Operating Assets		 - - 0.00 0.00 0.59 0.47 0.41 0.81 2.00 1.45 2.08
Total Liabilities & Shareholders' Equity		 1.39 2.17 2.22 1.71 11 9.83 36 61 74 88 73
Total Liabilities		 2.66 2.59 2.12 1.12 4.72 3.99 6.24 19 29 49 67
Total Current Liabilities		 1.46 1.39 2.12 1.12 2.64 3.54 6.02 13 14 15 19
Accounts Payable		 0.24 0.33 0.29 0.19 0.41 0.49 0.59 1.43 2.00 1.53 2.34
Accrued Expenses		 0.32 0.28 0.29 0.93 2.12 2.92 5.23 9.90 9.72 12 14
Other Current Liabilities		 0.45 0.41 - 0.00 0.12 0.13 0.20 1.48 1.46 0.36 0.59
Other Current Nonoperating Liabilities		 0.27 0.37 0.32 - - - - - - 1.05 1.23
Total Noncurrent Liabilities		 1.20 1.20 0.00 0.00 2.08 0.45 0.22 6.51 16 34 48
Long-Term Debt		 1.20 1.20 0.00 0.00 1.50 - - 0.00 11 32 47
Other Noncurrent Operating Liabilities		 - - - - 0.00 0.09 0.22 6.00 4.46 1.99 1.87
Commitments & Contingencies		 - - - - - 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -1.27 -0.42 0.10 0.59 6.39 5.84 30 42 45 39 5.93
Total Preferred & Common Equity		 -1.27 -0.42 0.10 0.59 6.61 6.15 31 42 45 39 5.94
Total Common Equity		 -2.07 -1.28 -0.75 -11 -4.75 6.15 31 42 45 39 5.94
Common Stock		 45 46 46 -11 -2.08 13 46 65 73 77 81
Retained Earnings		 -47 -47 -47 0.14 -2.68 -7.03 -15 -23 -28 -38 -75
Noncontrolling Interest		 - - - 0.00 -0.22 -0.31 -0.49 -0.11 -0.24 -0.49 -0.01

Quarterly Balance Sheets for Sanara MedTech

This table presents Sanara MedTech's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 75 71 73 89 96 99 71 69
Total Current Assets		 19 17 21 32 37 34 31 31
Cash & Equivalents		 6.24 2.83 6.15 16 21 17 15 14
Accounts Receivable		 7.45 9.22 11 12 12 12 12 14
Inventories, net		 5.02 4.23 3.56 3.01 3.16 3.51 3.39 3.12
Prepaid Expenses		 0.62 0.91 0.49 0.43 1.09 1.20 0.71 0.82
Other Current Nonoperating Assets		 - - - - - - 0.10 0.05
Plant, Property, & Equipment, net		 1.33 1.19 1.12 1.00 2.06 8.90 0.42 0.46
Total Noncurrent Assets		 55 53 51 56 57 56 39 38
Long-Term Investments		 3.08 3.08 3.08 8.32 11 11 13 14
Goodwill		 3.60 3.60 3.60 3.60 3.60 3.60 3.60 3.60
Intangible Assets		 46 44 43 42 42 41 21 18
Other Noncurrent Operating Assets		 2.09 1.89 1.79 1.69 1.17 1.09 2.15 1.99
Total Liabilities & Shareholders' Equity		 75 71 73 89 96 99 71 69
Total Liabilities		 31 28 32 49 60 63 65 62
Total Current Liabilities		 13 13 12 14 13 15 17 14
Accounts Payable		 2.00 1.28 0.90 1.45 2.14 1.49 1.17 0.92
Accrued Expenses		 9.67 9.18 9.19 11 11 13 14 12
Other Current Liabilities		 1.32 1.36 1.48 2.35 0.23 0.22 0.57 0.37
Other Current Nonoperating Liabilities		 - - - - - - 2.09 0.71
Total Noncurrent Liabilities		 18 15 20 35 46 48 48 49
Long-Term Debt		 11 11 16 31 45 45 46 47
Other Noncurrent Operating Liabilities		 6.72 4.40 4.17 3.41 1.86 3.16 1.96 1.77
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 44 43 41 39 37 35 6.15 7.02
Total Preferred & Common Equity		 44 43 42 40 37 35 6.14 7.03
Total Common Equity		 44 43 42 40 37 35 6.15 7.03
Common Stock		 72 73 75 76 78 79 80 82
Retained Earnings		 -28 -30 -33 -36 -41 -43 -74 -75
Noncontrolling Interest		 -0.22 -0.28 -0.30 -0.33 -0.00 -0.01 -0.01 -0.01

Annual Metrics And Ratios for Sanara MedTech

This table displays calculated financial ratios and metrics derived from Sanara MedTech's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 107,346,916.00 109,689,909.00 112,223,854.00 236,642,901.00 3,571,001.00 6,293,968.00 7,632,044.00 8,303,729.00 8,538,489.00 - 8,935,657.00
DEI Adjusted Shares Outstanding		 107,346,916.00 109,689,909.00 112,223,854.00 236,642,901.00 3,571,001.00 6,293,968.00 7,632,044.00 8,303,729.00 8,538,489.00 - 8,935,657.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.02 -0.01 0.00 0.00 -0.79 -0.69 -1.04 -0.96 -0.50 - -4.20
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 28.09% 63.33% 14.47% -7.41% 101.56% 32.47% 54.90% 89.87% 41.77% 33.36% 18.97%
EBITDA Growth		 49.32% 80.07% 239.57% -262.05% -539.65% -81.17% -43.37% -49.67% 94.73% -195.85% 80.57%
EBIT Growth		 51.36% 75.00% 170.93% -387.44% -454.95% -83.88% -46.94% -69.70% 66.33% -59.32% 481.13%
NOPAT Growth		 53.21% 71.80% 163.23% -391.67% -445.98% -83.74% -46.51% -69.70% 66.33% -59.32% 480.26%
Net Income Growth		 41.16% 68.98% 179.69% -281.27% -368.57% -57.96% -79.83% -1.23% 45.13% -123.25% -279.02%
EPS Growth		 33.33% 50.00% 100.00% 0.00% 0.00% 42.42% 0.00% 0.00% 48.00% -119.23% -282.46%
Operating Cash Flow Growth		 28.68% 134.02% -134.18% 298.15% -882.05% -86.15% -19.33% -15.38% 41.57% 99.27% 28,634.43%
Free Cash Flow Firm Growth		 -82.67% 84.85% -137.41% 155.21% -937.70% -86.76% -11.19% -363.45% 36.05% 83.86% -32.10%
Invested Capital Growth		 117.15% 58.95% 270.07% -64.75% 354.56% 148.77% 39.67% 365.64% 59.01% -2.81% -25.47%
Revenue Q/Q Growth		 -0.57% 23.21% -0.75% -22.04% 39.07% 10.15% 10.25% 22.05% 3.79% 11.04% 1.19%
EBITDA Q/Q Growth		 5.35% 73.61% -54.49% -1,038.95% -67.76% 11.84% -56.27% 8.17% 85.60% 21.01% 297.42%
EBIT Q/Q Growth		 4.96% 67.58% -62.44% -1,340.77% -59.43% 10.68% -53.17% 2.26% 40.73% -2.27% 425.48%
NOPAT Q/Q Growth		 -17.57% 71.13% -71.65% -466.00% -57.02% 10.81% -53.17% 2.26% 40.73% -2.27% 425.00%
Net Income Q/Q Growth		 -18.35% 57.10% 4.03% -547.79% -53.12% 21.90% -71.77% -8.11% 46.77% -16.97% 0.24%
EPS Q/Q Growth		 -100.00% 50.00% 0.00% 100.00% -60.98% 100.00% 0.00% 0.00% 0.00% -15.15% -3.32%
Operating Cash Flow Q/Q Growth		 8.33% 291.95% -1,885.55% 2.03% -105.10% 5.67% -32.95% 17.02% -6.69% 98.68% 79.84%
Free Cash Flow Firm Q/Q Growth		 -145.53% 56.62% -64.61% -44.53% -51.83% -5.21% 1.10% 1.64% -3.08% 22.97% -30.56%
Invested Capital Q/Q Growth		 -45.72% -23.79% -9.09% -16.73% 24.95% 31.51% -10.47% -3.51% 3.34% 0.97% -14.57%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 73.55% 82.87% 87.22% 91.31% 89.72% 89.63% 90.43% 86.12% 87.92% 90.61% 92.71%
EBITDA Margin		 -26.84% -3.28% 3.99% -6.99% -22.18% -30.34% -28.08% -22.13% -0.82% -1.83% 11.19%
Operating Margin		 -28.62% -4.94% 1.91% -8.60% -23.29% -32.30% -30.55% -27.30% -6.49% -7.75% 7.08%
EBIT Margin		 -28.62% -4.38% 2.71% -8.43% -23.20% -32.21% -30.55% -27.30% -6.49% -7.75% 7.09%
Profit (Net Income) Margin		 -39.75% -7.55% 5.25% -10.29% -23.92% -28.52% -33.11% -17.65% -6.83% -11.44% -36.43%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 99.24% 100.00% 100.00% 58.06% 100.00% 100.00% 9,556.28%
Interest Burden Percent		 138.87% 172.31% 193.60% 122.09% 103.88% 88.55% 108.37% 111.34% 105.33% 147.60% -5.37%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -74.33% 16.29% -44.62% -168.56% -108.34% -92.84% -47.80% -7.55% -9.93% 19.49%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -94.74% 39.72% -100.93% -130.46% -76.17% -70.08% -51.59% 28.59% -103.55% -1,098.97%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 123.40% -223.01% -129.63% 87.92% 35.66% 48.43% 25.31% -2.73% -13.81% -187.05%
Return on Equity (ROE)		 127.87% 49.07% -206.72% -174.25% -80.64% -72.68% -44.42% -22.49% -10.28% -23.74% -167.56%
Cash Return on Invested Capital (CROIC)		 -1,024.40% -119.86% -98.62% 51.14% -296.43% -193.65% -125.95% -177.08% -53.11% -7.08% 48.67%
Operating Return on Assets (OROA)		 -66.80% -13.54% 7.80% -25.05% -42.57% -47.94% -31.92% -25.69% -6.25% -8.29% 9.09%
Return on Assets (ROA)		 -92.76% -23.34% 15.10% -30.58% -43.88% -42.45% -34.59% -16.61% -6.58% -12.24% -46.66%
Return on Common Equity (ROCE)		 219.73% 97.12% -1,310.90% 2,915.63% 179.51% -8.30% -45.41% -22.64% -10.30% -23.95% -169.43%
Return on Equity Simple (ROE_SIMPLE)		 105.44% 98.27% 323.11% -102.35% -42.55% -72.27% -26.09% -19.40% -9.90% -25.15% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.68 -0.19 0.12 -0.35 -1.92 -3.52 -5.16 -8.76 -2.95 -4.70 5.11
NOPAT Margin		 -20.03% -3.46% 1.91% -6.02% -16.30% -22.61% -21.39% -19.11% -4.54% -5.42% 4.96%
Net Nonoperating Expense Percent (NNEP)		 116.63% 20.41% -23.44% 56.31% -38.10% -32.16% -22.76% 3.79% -36.14% 93.61% 1,118.46%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -5.25% -6.64% 9.75%
Cost of Revenue to Revenue		 26.45% 17.13% 12.78% 8.69% 10.28% 10.37% 9.57% 13.88% 12.08% 9.39% 7.29%
SG&A Expenses to Revenue		 100.19% 86.51% 83.67% 98.25% 111.05% 119.80% 116.19% 100.29% 87.70% 88.33% 76.34%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.26% 2.31% 7.34% 6.36% 6.58% 4.92%
Operating Expenses to Revenue		 102.17% 87.81% 85.31% 99.90% 113.01% 121.93% 120.98% 113.43% 94.40% 98.36% 85.62%
Earnings before Interest and Taxes (EBIT)		 -0.97 -0.24 0.17 -0.49 -2.73 -5.02 -7.38 -13 -4.22 -6.72 7.32
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -0.91 -0.18 0.25 -0.41 -2.61 -4.73 -6.78 -10 -0.53 -1.58 12
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 51.06 7.36 9.03 7.83 7.37 35.14
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 102.87 8.70 56.26 0.00 0.00 0.00
Price to Revenue (P/Rev)		 3.18 1.99 1.78 1.70 4.89 20.15 9.34 8.24 5.40 3.35 2.02
Price to Earnings (P/E)		 0.00 0.00 58.36 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 1.71% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 64.33 38.76 11.01 51.49 34.31 67.35 31.07 12.13 7.38 6.38 9.99
Enterprise Value to Revenue (EV/Rev)		 3.78 2.21 2.03 3.62 5.44 20.05 8.34 7.99 5.45 3.43 2.17
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 50.90 0.00 0.00 0.00 0.00 0.00 0.00 0.00 19.40
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 74.88 0.00 0.00 0.00 0.00 0.00 0.00 0.00 30.61
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 106.40 0.00 0.00 0.00 0.00 0.00 0.00 0.00 43.80
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 29.80 0.00 76.25 0.00 0.00 0.00 0.00 0.00 0.00 33.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 52.48 0.00 0.00 0.00 0.00 0.00 0.00 17.54
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -1.08 -2.85 11.70 0.00 0.31 0.06 0.00 0.01 0.26 0.82 7.85
Long-Term Debt to Equity		 -0.95 -2.84 0.00 0.00 0.31 0.06 0.00 0.01 0.25 0.82 7.85
Financial Leverage		 -0.54 -1.30 -5.61 1.28 -0.67 -0.47 -0.69 -0.49 -0.10 0.13 0.17
Leverage Ratio		 -1.38 -2.10 -13.69 5.70 1.84 1.71 1.28 1.35 1.56 1.94 3.59
Compound Leverage Factor		 -1.91 -3.62 -26.51 6.96 1.91 1.52 1.39 1.51 1.64 2.86 -0.19
Debt to Total Capital		 1,285.80% 154.19% 92.13% 0.00% 23.66% 5.74% 0.00% 1.19% 20.69% 45.05% 88.69%
Short-Term Debt to Total Capital		 162.77% 0.48% 92.13% 0.00% 0.00% 0.00% 0.00% 0.00% 1.03% 0.00% 0.00%
Long-Term Debt to Total Capital		 1,123.03% 153.71% 0.00% 0.00% 23.66% 5.74% 0.00% 1.19% 19.66% 45.05% 88.69%
Preferred Equity to Total Capital		 748.25% 109.70% 65.69% 1,937.32% 135.76% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% -2.65% -5.01% -1.62% -0.25% -0.43% -0.69% -0.02%
Common Equity to Total Capital		 -1,934.04% -163.90% -57.82% -1,837.32% -56.77% 99.27% 101.62% 98.81% 79.74% 55.64% 11.32%
Debt to EBITDA		 -1.52 -6.67 4.77 0.00 -0.76 -0.08 0.00 -0.05 -21.75 -20.16 4.03
Net Debt to EBITDA		 -1.32 -2.05 2.93 0.00 1.77 0.25 0.00 1.14 -6.36 -4.88 1.33
Long-Term Debt to EBITDA		 -1.33 -6.65 0.00 0.00 -0.76 -0.08 0.00 -0.05 -20.66 -20.16 4.03
Debt to NOPAT		 -2.04 -6.32 9.96 0.00 -1.03 -0.10 0.00 -0.06 -3.94 -6.79 9.10
Net Debt to NOPAT		 -1.77 -1.94 6.12 0.00 2.41 0.34 0.00 1.32 -1.15 -1.64 2.99
Long-Term Debt to NOPAT		 -1.78 -6.30 0.00 0.00 -1.03 -0.10 0.00 -0.06 -3.75 -6.79 9.10
Altman Z-Score		 -44.77 -25.39 -23.35 8.29 7.88 46.29 21.69 11.43 7.44 3.92 2.41
Noncontrolling Interest Sharing Ratio		 -71.84% -97.89% -534.13% 1,773.27% 322.60% 88.58% -2.22% -0.68% -0.28% -0.88% -1.12%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.79 1.43 0.96 1.51 3.35 1.27 4.09 1.61 1.38 2.18 1.80
Quick Ratio		 0.30 1.13 0.59 1.07 2.99 0.76 3.59 1.24 0.99 1.92 1.53
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -2.03 -0.31 -0.73 0.40 -3.37 -6.30 -7.00 -32 -21 -3.35 13
Operating Cash Flow to CapEx		 -22,551.35% 13,510.89% -318.63% 3,267.41% -1,187.46% -741.13% -2,801.31% -3,818.67% -1,226.61% -11.55% 148.65%
Free Cash Flow to Firm to Interest Expense		 -5.40 -1.76 0.00 4.65 -31.85 0.00 -9,851.55 0.00 -43.63 -1.07 1.89
Operating Cash Flow to Interest Expense		 -3.21 2.35 0.00 3.20 -20.46 0.00 -6,771.49 0.00 -6.82 -0.01 1.00
Operating Cash Flow Less CapEx to Interest Expense		 -3.22 2.33 0.00 3.10 -22.19 0.00 -7,013.21 0.00 -7.38 -0.07 0.33
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 2.33 3.09 2.87 2.97 1.83 1.49 1.04 0.94 0.96 1.07 1.28
Accounts Receivable Turnover		 12.73 11.06 8.24 6.46 10.20 8.90 9.36 9.31 8.45 7.87 8.07
Inventory Turnover		 2.20 2.49 1.52 0.86 2.00 1.71 1.45 2.27 1.90 2.18 2.24
Fixed Asset Turnover		 77.35 143.62 128.47 142.41 105.19 35.28 20.92 30.10 48.60 102.55 231.91
Accounts Payable Turnover		 3.93 3.28 2.61 2.12 4.04 3.59 4.25 6.30 4.58 4.61 3.89
Days Sales Outstanding (DSO)		 28.67 32.99 44.30 56.54 35.79 41.01 38.99 39.19 43.21 46.40 45.22
Days Inventory Outstanding (DIO)		 166.20 146.65 239.97 423.22 182.88 213.90 252.40 160.59 192.12 167.49 162.62
Days Payable Outstanding (DPO)		 92.83 111.28 139.78 172.06 90.41 101.71 85.98 57.98 79.68 79.20 93.89
Cash Conversion Cycle (CCC)		 102.04 68.36 144.49 307.70 128.26 153.20 205.42 141.81 155.65 134.69 113.95
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.20 0.31 1.16 0.41 1.87 4.64 6.48 30 48 47 22
Invested Capital Turnover		 -7.05 21.49 8.53 7.41 10.34 4.79 4.34 2.50 1.66 1.83 3.93
Increase / (Decrease) in Invested Capital		 1.35 0.12 0.85 -0.75 1.46 2.78 1.84 24 18 -1.35 -7.66
Enterprise Value (EV)		 13 12 13 21 64 313 201 366 354 297 224
Market Capitalization		 11 11 11 9.94 57 314 226 378 351 290 209
Book Value per Share		 ($0.02) ($0.01) ($0.01) ($0.05) ($1.33) $0.98 $4.01 $5.04 $5.25 $4.51 $0.66
Tangible Book Value per Share		 ($0.02) ($0.01) ($0.01) ($0.05) ($1.74) $0.49 $3.40 $0.81 ($0.43) ($0.60) ($1.82)
Total Capital		 0.11 0.78 1.30 0.59 8.37 6.20 30 42 56 71 52
Total Debt		 1.38 1.20 1.20 0.00 1.98 0.36 0.00 0.51 12 32 47
Total Long-Term Debt		 1.20 1.20 0.00 0.00 1.98 0.36 0.00 0.51 11 32 47
Net Debt		 1.20 0.37 0.74 -0.18 -4.63 -1.20 -24 -12 3.40 7.73 15
Capital Expenditures (CapEx)		 0.01 0.00 0.04 0.01 0.18 0.54 0.17 0.15 0.26 0.21 4.57
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.31 -0.23 0.66 0.39 -0.40 0.49 -0.07 -1.15 0.67 2.14 -1.66
Debt-free Net Working Capital (DFNWC)		 -0.13 0.61 1.12 0.57 6.22 0.94 19 7.81 5.82 18 15
Net Working Capital (NWC)		 -0.30 0.60 -0.08 0.57 6.22 0.94 19 7.81 5.24 18 15
Net Nonoperating Expense (NNE)		 0.66 0.23 -0.21 0.25 0.90 0.92 2.83 -0.67 1.49 5.21 43
Net Nonoperating Obligations (NNO)		 1.47 0.74 1.06 -0.18 -4.53 -1.20 -24 -12 3.40 7.73 16
Total Depreciation and Amortization (D&A)		 0.06 0.06 0.08 0.08 0.12 0.29 0.60 2.37 3.68 5.13 4.23
Debt-free, Cash-free Net Working Capital to Revenue		 -9.14% -4.14% 10.45% 6.71% -3.37% 3.12% -0.28% -2.51% 1.03% 2.47% -1.61%
Debt-free Net Working Capital to Revenue		 -3.73% 10.99% 17.80% 9.73% 52.83% 6.05% 76.98% 17.04% 8.95% 20.79% 14.46%
Net Working Capital to Revenue		 -8.91% 10.92% -1.24% 9.73% 52.83% 6.05% 76.98% 17.04% 8.06% 20.79% 14.46%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.02) ($0.01) $0.00 $0.00 ($1.32) ($0.76) ($1.08) ($1.00) ($0.52) ($1.14) ($4.36)
Adjusted Weighted Average Basic Shares Outstanding		 106.70M 108.60M 111.38M 217.16M 2.13M 5.73M 7.81M 7.91M 8.28M 8.48M 8.62M
Adjusted Diluted Earnings per Share		 ($0.02) ($0.01) $0.00 $0.00 ($1.32) ($0.76) ($1.08) $0.00 ($0.52) ($1.14) ($4.36)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 110.54M 208.65M 217.16M 2.13M 5.73M 7.81M 8.38M 8.28M 8.48M 8.62M
Adjusted Basic & Diluted Earnings per Share		 ($0.02) ($0.01) $0.00 $0.00 $0.00 $0.00 ($1.08) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 110.54M 236.64M 0.00 6.02M 7.62M 7.34M 8.38M 8.62M 8.90M 9.17M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.68 -0.19 0.08 -0.35 -1.92 -3.52 -5.16 -8.76 -2.95 -4.70 6.40
Normalized NOPAT Margin		 -20.03% -3.46% 1.34% -6.02% -16.30% -22.61% -21.39% -19.11% -4.54% -5.42% 6.21%
Pre Tax Income Margin		 -39.75% -7.55% 5.25% -10.29% -24.10% -28.52% -33.11% -30.40% -6.83% -11.44% -0.38%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -2.57 -1.38 0.00 -5.68 -25.77 0.00 -10,374.34 0.00 -8.86 -2.15 1.08
NOPAT to Interest Expense		 -1.80 -1.09 0.00 -4.06 -18.11 0.00 -7,262.04 0.00 -6.20 -1.50 0.76
EBIT Less CapEx to Interest Expense		 -2.59 -1.40 0.00 -5.78 -27.50 0.00 -10,616.07 0.00 -9.42 -2.21 0.41
NOPAT Less CapEx to Interest Expense		 -1.81 -1.11 0.00 -4.16 -19.83 0.00 -7,503.77 0.00 -6.76 -1.57 0.08
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% -7.11% 0.00% -2.50% -2.72% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% -7.11% 0.00% -2.50% -2.72% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Sanara MedTech

This table displays calculated financial ratios and metrics derived from Sanara MedTech's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 8,521,872.00 8,538,489.00 8,622,805.00 8,625,201.00 8,746,976.00 - 8,901,903.00 8,887,853.00 8,902,351.00 8,935,657.00 9,167,040.00
DEI Adjusted Shares Outstanding		 8,521,872.00 8,538,489.00 8,622,805.00 8,625,201.00 8,746,976.00 - 8,901,903.00 8,887,853.00 8,902,351.00 8,935,657.00 9,167,040.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.12 -0.03 -0.20 -0.41 -0.33 - -0.40 -0.23 -3.42 -0.18 0.05
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 22.85% 15.50% 19.42% 27.97% 35.24% 48.70% 26.42% 28.14% 21.51% 4.61% 18.62%
EBITDA Growth		 103.85% 137.76% 3.26% -58.27% 1,975.47% 48.28% 577.35% 168.77% 109.85% 9.93% 63.72%
EBIT Growth		 71.95% 92.76% -25.93% -54.59% 185.87% -65.88% 154.61% 98.91% 277.79% 32.22% 216.40%
NOPAT Growth		 71.95% 92.76% -25.93% -54.59% 185.87% -65.88% 153.90% 98.91% 439.70% 32.22% 357.99%
Net Income Growth		 28.40% 93.70% -47.91% -89.11% -163.30% -547.99% -96.07% 42.81% -954.86% 5.32% 113.00%
EPS Growth		 27.78% 0.00% -50.00% -86.36% -161.54% -500.00% -95.24% 43.90% -900.00% -77.78% 112.20%
Operating Cash Flow Growth		 164.77% -31.55% 8.44% 17.90% 92.69% 209.84% -25.37% 288.68% 6.14% 323.27% -23.34%
Free Cash Flow Firm Growth		 39.94% 30.59% 22.47% -38.52% 105.01% 106.05% 97.31% 73.89% 2,792.79% -38.09% 5,211.52%
Invested Capital Growth		 48.47% 59.01% 57.05% 52.16% -0.53% -2.81% 2.22% 9.99% -43.22% -25.47% -46.43%
Revenue Q/Q Growth		 1.73% 10.39% 4.79% 8.75% 7.50% 21.38% -10.92% 10.23% 1.95% 4.50% 1.01%
EBITDA Q/Q Growth		 108.76% 836.75% -148.54% -297.34% 214.88% 267.72% -69.23% 229.02% 250.54% 78.02% -54.17%
EBIT Q/Q Growth		 51.42% 75.07% -577.76% -88.34% 126.99% 80.52% -82.92% 98.49% 9,482.54% 120.13% -59.12%
NOPAT Q/Q Growth		 51.42% 75.07% -577.76% -88.34% 126.99% 80.52% -88.20% 98.49% 13,503.63% 120.13% -59.12%
Net Income Q/Q Growth		 41.33% 76.03% -585.50% -96.17% 18.31% 41.01% -107.42% 42.78% -1,406.74% 94.71% 128.48%
EPS Q/Q Growth		 40.91% 76.92% -600.00% -95.24% 17.07% 47.06% -127.78% 43.90% -1,378.26% 90.59% 115.63%
Operating Cash Flow Q/Q Growth		 161.87% -179.74% -87.90% 11.44% 245.22% -54.54% -314.46% 233.27% -18.30% 81.26% -162.49%
Free Cash Flow Firm Q/Q Growth		 -17.54% -13.75% -4.58% 0.93% 104.25% 198.90% -102.21% -91.46% 571.24% -38.30% 82.55%
Invested Capital Q/Q Growth		 45.95% 3.34% 1.64% -0.74% -4.59% 0.97% 65.84% 6.81% -50.74% -14.57% 19.20%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 89.07% 89.89% 89.80% 90.04% 90.81% 91.45% 92.17% 92.50% 92.88% 93.19% 93.08%
EBITDA Margin		 0.58% 4.93% -2.28% -8.34% 8.91% 4.91% 8.62% 4.48% 15.39% 26.22% 11.90%
Operating Margin		 -5.66% -1.28% -8.26% -14.31% 3.59% -1.43% 3.52% -0.12% 11.17% 23.53% 9.52%
EBIT Margin		 -5.66% -1.28% -8.26% -14.31% 3.59% -1.43% 3.57% -0.12% 11.17% 23.53% 9.52%
Profit (Net Income) Margin		 -6.83% -1.48% -9.71% -17.51% -13.30% -6.46% -15.05% -7.81% -115.49% -5.85% 1.65%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 1,597.36% 100.00% 568.41% 100.00% -3,644.38% -37.20% 115.32%
Interest Burden Percent		 120.77% 116.13% 117.45% 122.34% -23.18% 453.63% -74.19% 6,438.68% 28.37% 66.84% 15.03%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -6.38% -1.49% -9.85% -18.08% 4.24% -1.83% 4.58% -0.16% 31.43% 92.47% 26.73%
ROIC Less NNEP Spread (ROIC-NNEP)		 1.97% 1.04% 21.38% 112.39% -71.25% -27.66% -38.74% -16.22% -217.27% -119.39% 13.42%
Return on Net Nonoperating Assets (RNNOA)		 -0.24% -0.10% -1.18% -3.15% -7.75% -3.69% -9.21% -5.25% -127.79% -20.32% 10.10%
Return on Equity (ROE)		 -6.63% -1.59% -11.03% -21.23% -3.51% -5.52% -4.64% -5.41% -96.36% 72.15% 36.83%
Cash Return on Invested Capital (CROIC)		 -51.83% -53.11% -52.33% -51.05% -5.31% -7.08% 2.94% -15.59% 50.78% 48.67% 84.30%
Operating Return on Assets (OROA)		 -5.17% -1.23% -8.59% -15.74% 3.42% -1.53% 3.91% -0.14% 14.26% 30.13% 12.35%
Return on Assets (ROA)		 -6.25% -1.43% -10.09% -19.26% -12.66% -6.92% -16.48% -8.83% -147.44% -7.49% 2.14%
Return on Common Equity (ROCE)		 -6.70% -1.59% -11.09% -21.31% -3.53% -5.56% -4.65% -5.44% -97.06% 72.95% 36.83%
Return on Equity Simple (ROE_SIMPLE)		 -18.82% 0.00% -11.60% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.63 -0.16 -1.07 -2.02 0.54 -0.26 0.58 -0.02 2.94 6.47 2.65
NOPAT Margin		 -3.96% -0.89% -5.78% -10.02% 2.51% -1.00% 2.47% -0.09% 11.17% 23.53% 9.52%
Net Nonoperating Expense Percent (NNEP)		 -8.35% -2.53% -31.24% -130.47% 75.49% 25.84% 43.31% 16.06% 248.70% 211.86% 13.31%
Return On Investment Capital (ROIC_SIMPLE)		 - -0.28% -1.96% -3.50% 0.77% -0.37% 0.71% -0.03% 5.68% 12.34% 4.92%
Cost of Revenue to Revenue		 10.93% 10.11% 10.20% 9.96% 9.19% 8.55% 7.83% 7.50% 7.12% 6.81% 6.92%
SG&A Expenses to Revenue		 86.60% 92.35% 87.35% 94.04% 80.38% 85.22% 81.63% 83.44% 75.48% 57.58% 78.71%
R&D to Revenue		 6.16% 3.68% 5.11% 4.89% 3.62% 9.17% 4.06% 4.87% 3.91% 6.07% 2.73%
Operating Expenses to Revenue		 94.73% 91.17% 98.07% 104.41% 87.22% 92.87% 88.65% 92.62% 81.71% 69.70% 83.56%
Earnings before Interest and Taxes (EBIT)		 -0.91 -0.23 -1.53 -2.88 0.78 -0.37 0.84 -0.03 2.94 6.47 2.65
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 0.09 0.87 -0.42 -1.68 1.93 1.29 2.02 1.16 4.05 7.22 3.31
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 5.99 7.83 7.37 5.84 6.65 7.37 7.49 7.13 45.94 35.14 22.41
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 4.24 5.40 4.69 3.36 3.39 3.35 3.00 2.59 2.77 2.02 1.47
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 5.76 7.38 6.65 5.17 5.86 6.38 5.78 5.07 11.46 9.99 6.61
Enterprise Value to Revenue (EV/Rev)		 4.27 5.45 4.77 3.45 3.47 3.43 3.15 2.78 2.95 2.17 1.64
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 387.67 0.00 32.60 345.46 103.50 19.40 13.76
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 79.40 0.00 0.00 30.61 19.34
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 113.77 0.00 0.00 43.80 19.34
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 74.07 79.65 33.00 27.93
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 198.79 0.00 16.34 17.54 5.47
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.26 0.26 0.27 0.39 0.79 0.82 1.22 1.28 7.42 7.85 6.67
Long-Term Debt to Equity		 0.26 0.25 0.25 0.39 0.79 0.82 1.22 1.28 7.42 7.85 6.67
Financial Leverage		 -0.12 -0.10 -0.06 -0.03 0.11 0.13 0.24 0.32 0.59 0.17 0.75
Leverage Ratio		 1.54 1.56 1.55 1.59 1.96 1.94 2.10 2.24 3.50 3.59 3.79
Compound Leverage Factor		 1.86 1.81 1.82 1.95 -0.46 8.80 -1.56 144.32 0.99 2.40 0.57
Debt to Total Capital		 20.92% 20.69% 21.35% 28.19% 44.27% 45.05% 54.86% 56.15% 88.12% 88.69% 86.95%
Short-Term Debt to Total Capital		 0.42% 1.03% 1.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 20.50% 19.66% 19.66% 28.19% 44.27% 45.05% 54.86% 56.15% 88.12% 88.69% 86.95%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 -0.39% -0.43% -0.51% -0.53% -0.47% -0.69% 0.00% -0.01% -0.02% -0.02% -0.02%
Common Equity to Total Capital		 79.48% 79.74% 79.16% 72.34% 56.20% 55.64% 45.14% 43.85% 11.88% 11.32% 13.06%
Debt to EBITDA		 -3.14 -21.75 -22.43 -14.26 44.84 -20.16 5.04 57.97 15.71 4.03 3.65
Net Debt to EBITDA		 -0.63 -6.36 -11.07 -6.15 9.64 -4.88 1.49 22.84 6.23 1.33 1.48
Long-Term Debt to EBITDA		 -3.08 -20.66 -20.64 -14.26 44.84 -20.16 5.04 57.97 15.71 4.03 3.65
Debt to NOPAT		 -2.34 -3.94 -3.68 -4.18 -11.59 -6.79 17.61 -14.69 -29.00 9.10 5.13
Net Debt to NOPAT		 -0.47 -1.15 -1.82 -1.81 -2.49 -1.64 5.21 -5.79 -11.50 2.99 2.09
Long-Term Debt to NOPAT		 -2.30 -3.75 -3.39 -4.18 -11.59 -6.79 17.61 -14.69 -29.00 9.10 5.13
Altman Z-Score		 5.45 7.61 7.23 4.94 3.81 4.16 3.43 2.99 2.96 2.37 1.99
Noncontrolling Interest Sharing Ratio		 -1.16% -0.28% -0.50% -0.37% -0.66% -0.88% -0.35% -0.40% -0.72% -1.12% -0.02%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.46 1.38 1.35 1.80 2.23 2.18 2.77 2.26 1.80 1.80 2.28
Quick Ratio		 1.03 0.99 0.95 1.45 1.99 1.92 2.45 1.95 1.56 1.53 1.99
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -16 -18 -19 -19 0.79 1.09 -0.50 -4.86 23 14 26
Operating Cash Flow to CapEx		 624.79% -1,563.37% -2,422.39% -2,402.79% 22,542.54% 1,291.42% -120.22% 151.25% 205.42% 4,801.74% -5,632.38%
Free Cash Flow to Firm to Interest Expense		 -83.89 -62.50 -70.29 -28.89 0.85 0.84 -0.38 -2.71 12.60 7.71 14.34
Operating Cash Flow to Interest Expense		 5.65 -2.95 -5.96 -2.19 2.21 0.72 -1.52 1.49 1.20 2.15 -1.37
Operating Cash Flow Less CapEx to Interest Expense		 4.75 -3.14 -6.21 -2.28 2.20 0.67 -2.78 0.50 0.61 2.11 -1.39
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.91 0.96 1.04 1.10 0.95 1.07 1.09 1.13 1.28 1.28 1.30
Accounts Receivable Turnover		 9.68 8.45 8.66 8.15 7.95 7.87 8.67 8.60 8.39 8.07 8.42
Inventory Turnover		 1.93 1.90 1.99 1.86 1.91 2.18 2.19 2.26 2.47 2.24 2.42
Fixed Asset Turnover		 44.76 48.60 53.83 61.45 67.21 102.55 56.40 19.42 144.24 231.91 85.47
Accounts Payable Turnover		 5.76 4.58 4.91 7.41 4.44 4.61 4.73 6.72 6.03 3.89 4.98
Days Sales Outstanding (DSO)		 37.71 43.21 42.16 44.78 45.92 46.40 42.10 42.43 43.48 45.22 43.33
Days Inventory Outstanding (DIO)		 189.46 192.12 183.55 195.93 190.83 167.49 166.78 161.16 147.80 162.62 150.62
Days Payable Outstanding (DPO)		 63.35 79.68 74.28 49.29 82.15 79.20 77.12 54.33 60.54 93.89 73.36
Cash Conversion Cycle (CCC)		 163.82 155.65 151.43 191.42 154.60 134.69 131.76 149.26 130.74 113.95 120.60
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 46 48 49 48 46 47 50 53 26 22 27
Invested Capital Turnover		 1.61 1.66 1.70 1.80 1.69 1.83 1.86 1.91 2.81 3.93 2.81
Increase / (Decrease) in Invested Capital		 15 18 18 17 -0.25 -1.35 1.08 4.84 -20 -7.66 -23
Enterprise Value (EV)		 267 354 325 250 271 297 288 270 301 224 177
Market Capitalization		 265 351 319 243 265 290 275 252 282 209 157
Book Value per Share		 $5.20 $5.25 $5.02 $4.84 $4.55 $4.51 $4.12 $3.98 $0.69 $0.66 $0.77
Tangible Book Value per Share		 ($0.62) ($0.43) ($0.49) ($0.57) ($0.67) ($0.60) ($1.00) ($1.03) ($2.08) ($1.82) ($1.57)
Total Capital		 56 56 55 58 71 71 81 81 52 52 54
Total Debt		 12 12 12 16 31 32 45 45 46 47 47
Total Long-Term Debt		 11 11 11 16 31 32 45 45 46 47 47
Net Debt		 2.34 3.40 5.77 7.01 6.74 7.73 13 18 18 15 19
Capital Expenditures (CapEx)		 0.17 0.05 0.07 0.06 0.01 0.07 1.66 1.76 1.06 0.08 0.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.14 0.67 2.54 3.10 1.29 2.14 2.87 1.83 -1.07 -1.66 3.90
Debt-free Net Working Capital (DFNWC)		 6.38 5.82 5.37 9.25 18 18 24 19 14 15 17
Net Working Capital (NWC)		 6.15 5.24 4.44 9.25 18 18 24 19 14 15 17
Net Nonoperating Expense (NNE)		 0.46 0.10 0.73 1.51 3.43 1.44 4.11 2.00 33 8.08 2.19
Net Nonoperating Obligations (NNO)		 2.34 3.40 5.77 7.01 6.74 7.73 13 18 20 16 20
Total Depreciation and Amortization (D&A)		 1.00 1.10 1.11 1.20 1.15 1.67 1.18 1.19 1.11 0.74 0.66
Debt-free, Cash-free Net Working Capital to Revenue		 0.23% 1.03% 3.74% 4.27% 1.65% 2.47% 3.14% 1.89% -1.05% -1.61% 3.63%
Debt-free Net Working Capital to Revenue		 10.19% 8.95% 7.90% 12.77% 22.51% 20.79% 25.73% 19.33% 13.61% 14.46% 16.28%
Net Working Capital to Revenue		 9.82% 8.06% 6.53% 12.77% 22.51% 20.79% 25.73% 19.33% 13.61% 14.46% 16.28%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.13) ($0.03) ($0.21) ($0.41) ($0.34) ($0.18) ($0.41) ($0.23) ($3.52) ($0.20) $0.05
Adjusted Weighted Average Basic Shares Outstanding		 8.33M 8.28M 8.42M 8.47M 8.52M 8.48M 8.57M 8.61M 8.65M 8.62M 8.71M
Adjusted Diluted Earnings per Share		 ($0.13) ($0.03) ($0.21) ($0.41) ($0.34) ($0.18) ($0.41) ($0.23) ($3.40) ($0.32) $0.05
Adjusted Weighted Average Diluted Shares Outstanding		 8.33M 8.28M 8.42M 8.47M 8.52M 8.48M 8.57M 8.61M 8.94M 8.62M 8.99M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 8.54M 8.62M 8.63M 8.75M 8.74M 8.90M 8.89M 8.90M 8.94M 9.17M 9.16M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.63 -0.16 -1.07 -2.02 0.54 -0.26 0.58 -0.02 2.06 4.53 1.85
Normalized NOPAT Margin		 -3.96% -0.89% -5.78% -10.02% 2.51% -1.00% 2.47% -0.09% 7.82% 16.47% 6.66%
Pre Tax Income Margin		 -6.83% -1.48% -9.71% -17.51% -0.83% -6.46% -2.65% -7.81% 3.17% 15.73% 1.43%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -4.82 -0.79 -5.73 -4.48 0.84 -0.29 0.64 -0.02 1.62 3.53 1.47
NOPAT to Interest Expense		 -3.37 -0.55 -4.01 -3.13 0.59 -0.20 0.44 -0.01 1.62 3.53 1.47
EBIT Less CapEx to Interest Expense		 -5.72 -0.97 -5.98 -4.57 0.83 -0.35 -0.63 -1.00 1.04 3.49 1.45
NOPAT Less CapEx to Interest Expense		 -4.28 -0.74 -4.26 -3.23 0.58 -0.26 -0.82 -1.00 1.04 3.49 1.45
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Sanara MedTech (NASDAQ: SMTI) showed a mixed but somewhat improving operating picture in Q1 2026, with revenue still growing and the company swinging back to a small profit on the income statement. However, the balance sheet remains highly leveraged, and cash flow was negative in the quarter, which is an important risk for retail investors to watch.

For the quarter ended March 31, 2026, revenue rose to $27.8 million, up from $27.5 million in Q4 2025 and $23.4 million in Q1 2025. Gross profit also remained strong at $25.9 million, reflecting a very healthy gross margin profile. But SG&A expenses were still large at $21.9 million, and interest expense continued to weigh on results.

Most notably, SMTI posted net income attributable to common shareholders of $459,000 in Q1 2026, a sharp improvement from the $1.6 million loss in Q4 2025 and the $3.5 million loss in Q1 2025. That said, the quarter’s profitability was modest and may not yet signal a durable turnaround.

Cash flow was weaker than earnings suggest. Operating cash flow came in at negative $2.5 million, compared with positive $3.9 million in Q4 2025. The company also used cash in investing and financing activities, ending the quarter with a net cash decrease of $3.0 million.

The balance sheet remains the biggest concern. As of March 31, 2026, SMTI had $13.6 million in cash, $69.3 million in total assets, and $62.3 million in total liabilities. Long-term debt was a sizable $46.8 million, while equity was only $7.0 million. That leaves very limited cushion if operating performance softens.

  • Revenue continued to grow, rising to $27.8 million in Q1 2026 from $23.4 million in Q1 2025.
  • Gross profit stayed strong at $25.9 million, indicating solid product-level economics.
  • Net income turned positive for common shareholders in Q1 2026 after a loss in the prior quarter.
  • Depreciation and amortization are helping reported earnings, showing the business still has meaningful non-cash support to profits.
  • Quarterly revenue growth was modest versus Q4 2025, so the top line is improving but not accelerating sharply.
  • Equity improved slightly to $7.0 million, but it remains thin relative to liabilities.
  • Cash fell during the quarter, but the ending balance still leaves some near-term liquidity.
  • Operating cash flow was negative at $2.5 million in Q1 2026.
  • Long-term debt remains very high at $46.8 million, creating ongoing interest burden and balance sheet risk.
  • SG&A expenses are still heavy at $21.9 million, limiting the company’s ability to convert gross profit into sustained bottom-line growth.

Bottom line: Sanara MedTech’s Q1 2026 results suggest incremental improvement in profitability, but the company is still carrying a debt-heavy balance sheet and has not yet proven that it can consistently generate positive operating cash flow. For investors, the story remains one of improving earnings quality, but with meaningful financial risk still attached.

07/04/26 01:16 PM ETAI Generated. May Contain Errors.

Sanara MedTech Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Sanara MedTech's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Sanara MedTech's net income appears to be on an upward trend, with a most recent value of -$37.57 million in 2025, rising from -$1.34 million in 2015. The previous period was -$9.91 million in 2024. See Sanara MedTech's forecast for analyst expectations on what's next for the company.

Sanara MedTech's total operating income in 2025 was $7.30 million, based on the following breakdown:
  • Total Gross Profit: $95.60 million
  • Total Operating Expenses: $88.29 million

Over the last 10 years, Sanara MedTech's total revenue changed from $3.37 million in 2015 to $103.12 million in 2025, a change of 2,957.9%.

Sanara MedTech's total liabilities were at $67.01 million at the end of 2025, a 36.3% increase from 2024, and a 2,416.4% increase since 2015.

In the past 10 years, Sanara MedTech's cash and equivalents has ranged from $176.42 thousand in 2018 to $18.65 million in 2021, and is currently $16.58 million as of their latest financial filing in 2025.

Over the last 10 years, Sanara MedTech's book value per share changed from -0.02 in 2015 to 0.66 in 2025, a change of -3,543.5%.


Related Companies

Financial statements for NASDAQ:SMTI last updated on 7/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
He turned $12,415 into millions. Now he wants to help you.
Tim Sykes turned $12,415 in bar mitzvah money into over $7 million in trading profits - and more than 50 of hi...
Tim Sykes | Sponsoredtc pixel
The Warsh Fed and what it could mean for your savings
The Fed just changed hands, and Reagan Gold Group says there may be a short window before the impact shows up ...
Reagan Gold Group | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
The cat is out the bag
Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...
Porter & Company | Sponsoredtc pixel
The pre-flight check for options traders
Pilots never skip their pre-flight checklist - and neither should options traders. The Smart Trade Options Che...
Profits Run | Sponsoredtc pixel
Are we ignoring the same signal Wall Street ignored in 1929?
In 1929, a 20-something broker named Irving Weiss shorted the market before Black Monday and made a fortune. H...
Weiss Ratings | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
They proved it worked in '76. Then buried it.
In 1976, Chevron, Unocal, and Texaco each confirmed the same energy technology worked - no fuel costs, no carb...
Behind the Markets | Sponsoredtc pixel